Table 1.
Ten-Year Risks of Diagnosis of Acquired Immune Deficiency Syndrome or Death From Any Cause According to Injection Drug Use in the Women’s Interagency HIV Study, United States, 1995–2006
| Approach | No. of Participants | No. of AIDS Diagnoses or Deaths | 10-Year Risk | 10-Year Risk Difference | 95% CI |
|---|---|---|---|---|---|
| Crude | |||||
| Injection drug use | 439 | 272 | 64.0 | 18.5 | 12.5, 24.5 |
| Nonuse | 725 | 307 | 45.5 | 0 | |
| IP-weighteda | |||||
| Injection drug use | 439 | 272 | 63.0 | 16.0 | 10.0, 22.1 |
| Nonuse | 725 | 307 | 47.0 | 0 | |
| Bounded | |||||
| Injection drug use | 439 | 272 and 1,023b | 23.4 and 87.9b | −49.4 to 61.5 | −52.3, 64.3 |
| Nonuse | 725 | 847 and 307b | 72.7 and 26.4b | 0 |
Abbreviations: AIDS, acquired immune deficiency syndrome; CI, confidence interval; HIV, human immunodeficiency virus; IP, inverse probability.
a Accounting for race (black or not) and for age in years and nadir CD4 cell count (cells/mm3), both at baseline.
b First and second numbers are for best and worst case for injection drug use, respectively.